The effect of novel therapies in high-molecular-risk multiple myeloma.

about

The effect of novel therapies in high-molecular-risk multiple myeloma.

Item

http://www.wikidata.org/entity/Q47375990

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The effect of novel therapies in high-molecular-risk multiple myeloma.

@en

The effect of novel therapies in high-molecular-risk multiple myeloma.

@nl

type

Item

label

The effect of novel therapies in high-molecular-risk multiple myeloma.

@en

The effect of novel therapies in high-molecular-risk multiple myeloma.

@nl

prefLabel

The effect of novel therapies in high-molecular-risk multiple myeloma.

@en

The effect of novel therapies in high-molecular-risk multiple myeloma.

@nl

P1476

The effect of novel therapies in high-molecular-risk multiple myeloma.

@en

P2093

Ajai Chari

http://www.w3.org/2001/XMLSchema#string

Deepu Madduri

http://www.w3.org/2001/XMLSchema#string

Douglas Tremblay

http://www.w3.org/2001/XMLSchema#string

Erin Moshier

http://www.w3.org/2001/XMLSchema#string

Guido Lancman

http://www.w3.org/2001/XMLSchema#string

Hearn Jay Cho

http://www.w3.org/2001/XMLSchema#string

Kevin Barley

http://www.w3.org/2001/XMLSchema#string

Samir Parekh

http://www.w3.org/2001/XMLSchema#string

Sundar Jagannath

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.

Curing myeloma at last: defining criteria and providing the evidence.

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

P304

870-879

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bart Barlogie

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29200420

http://www.w3.org/2001/XMLSchema#string

P932

5993678

http://www.w3.org/2001/XMLSchema#string